ClinicalTrials.gg
Active, not recruitingNCT05553834Updated Nov 4, 2026Results posted

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

A Phase 2 interventional study of Alirocumab and Cemiplimab in Non-small Cell Lung Cancer (NSCLC), sponsored by Duke University. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Duke University · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 19 open to participants now, 23 under way, 4 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 30
60 · median 62
Started
2023
with 2 others
Phase 2
19 of 30
13 open now
Primary completion
2025-09
later than 1 of 22 live
Registered
8th of 30
by date
Lead sponsor
2 of 30
Duke University

Among the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 3 that started in 2023, is one of 19 in phase 2, reaches primary completion later than 1 of the 22 other live ones, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

19 of the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented recurrent and/or non-small cell lung cancer
  • Progression after prior directed therapy (as monotherapy or in combination with chemotherapy and/or anti-CTLA4, or anti-VEGF agents) - defined as investigator assessed progression from prior treatment
  • If molecularly altered NSCLC including EGFR, ALK, ROS1, MET exon 14, RET, BRAF, NTRK, progression on prior targeted therapy is required
  • by 1.1
  • Performance Status 0 or 1
  • Signed written
  • Minimum of 4 weeks from any other experimental anti-cancer therapies or prior PD-1 treatment
  • Meet all the laboratory criteria per protocol

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PCSK9 inhibitors
  • Cardiac issues including MI, uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications.
  • Uncontrolled diabetes mellitus, defined as > 10
  • Major surgery less than 4 weeks prior to study enrollment
  • Another malignant condition diagnosed within 3 years of study enrollment
  • Intolerance to prior /L1 treatment including discontinuation for severe or recurrent severe toxicity (including myocarditis or other myocardiotoxity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyperthyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, Type 1 Diabetes, thrombocytopenia) or developed an immune checkpoint blockade related immune adverse event that was to and required additional systemic medication.
  • Known history of seropositivity or known acquired immunodeficiency syndrome (AIDS)
  • Additional exclusion criterion as per listed in the protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Alirocumab and Cemiplimab

    Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab

    Combination Product: Alirocumab and Cemiplimab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria

    A partial response (PR) under RECIST 1.1 guidelines indicates there is at least a 30% decrease in the sum of the longest diameters of target tumors, compared to the baseline measurement.

    Time frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1

Secondary outcomes

  1. Number of Participants Who Experienced an Adverse Event

    A measurement of the safety and tolerability of the combination regimen. Toxicity analysis will be performed on a continual basis following CTC V 5.0 criteria.

    Time frame: Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason

  2. Progression Free Survival (PFS) Per RECIST 1.1. Criteria

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or unequivocal progression of non-target lesion(s), or the appearance of new lesion(s), or death

    Time frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks

  3. Overall Survival (OS)

    Overall survival (OS) is the length of time that participants remain alive.

    Time frame: Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks

07

Results

Posted Nov 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Alirocumab and Cemiplimab
Started60
Completed60
Not completed0

Outcome measures

PrimaryNumber of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria

A partial response (PR) under RECIST 1.1 guidelines indicates there is at least a 30% decrease in the sum of the longest diameters of target tumors, compared to the baseline measurement.

Time frame:
Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1
Reported as:
Count of participants · Participants
Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria
ParticipantsExperimental: Alirocumab and Cemiplimab
Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria5
SecondaryNumber of Participants Who Experienced an Adverse Event

A measurement of the safety and tolerability of the combination regimen. Toxicity analysis will be performed on a continual basis following CTC V 5.0 criteria.

Time frame:
Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event
ParticipantsExperimental: Alirocumab and Cemiplimab
Number of Participants Who Experienced an Adverse Event56
SecondaryProgression Free Survival (PFS) Per RECIST 1.1. Criteria

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or unequivocal progression of non-target lesion(s), or the appearance of new lesion(s), or death

Time frame:
Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks
Reported as:
Median · months
Progression Free Survival (PFS) Per RECIST 1.1. Criteria
monthsExperimental: Alirocumab and Cemiplimab
Progression Free Survival (PFS) Per RECIST 1.1. Criteria2.52 (1.5 to 3.0)
SecondaryOverall Survival (OS)

Overall survival (OS) is the length of time that participants remain alive.

Time frame:
Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks
Reported as:
Median · months
Overall Survival (OS)
monthsExperimental: Alirocumab and Cemiplimab
Overall Survival (OS)7.04 (5.25 to 11.64)

Adverse events

Collected over Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Alirocumab and Cemiplimab48/60 (80%)29/60 (48.3%)56/60 (93.3%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventExperimental: Alirocumab and Cemiplimab
Nervous system disorders - Other, specifyNervous system disorders3/60
Pleural effusionRespiratory, thoracic and mediastinal disorders3/60
HypotensionVascular disorders3/60
Atrial fibrillationCardiac disorders2/60
Sinus tachycardiaCardiac disorders2/60
Adrenal insufficiencyEndocrine disorders2/60
General disorders and administration site conditions - Other, specifyGeneral disorders2/60
PainGeneral disorders2/60
FractureInjury, poisoning and procedural complications2/60
Spinal fractureInjury, poisoning and procedural complications2/60
Most frequent other events
Showing 10 of 137
Most frequent other events
EventExperimental: Alirocumab and Cemiplimab
AnemiaBlood and lymphatic system disorders24/60
HypoalbuminemiaMetabolism and nutrition disorders22/60
HyponatremiaMetabolism and nutrition disorders19/60
FatigueGeneral disorders15/60
Alkaline phosphatase increasedInvestigations14/60
HyperglycemiaMetabolism and nutrition disorders14/60
HypocalcemiaMetabolism and nutrition disorders14/60
NauseaGastrointestinal disorders13/60
CoughRespiratory, thoracic and mediastinal disorders12/60
Investigations - Other, specifyInvestigations11/60

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Alirocumab and Cemiplimab
<=18 years0
Between 18 and 65 years16
>=65 years44
Age, Continuous
Age, Continuous(years)Alirocumab and Cemiplimab
Mean68.6 ± 7.96
Sex: Female, Male
Sex: Female, Male(Participants)Alirocumab and Cemiplimab
Female28
Male32
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alirocumab and Cemiplimab
Hispanic or Latino0
Not Hispanic or Latino58
Unknown or Not Reported2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alirocumab and Cemiplimab
Black or African American12
White44
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(Participants)Alirocumab and Cemiplimab
United States60
08

Study locations

2 sites
09

References and documents

Publications

  • Oduah EI, Zhang T, Jung SH, Stinchcombe TE, Ready N, Crawford J, Clarke JM, Gray JE, Antonia SJ. Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study. Future Oncol. 2026 Apr;22(9):1065-1072. doi: 10.1080/14796694.2026.2648863. Epub 2026 Apr 6. PubMed 41940540 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Sep 2025, 28 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 28 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2022
First posted
Sep 23, 2022
StartActual
May 16, 2023
Primary completionActual
Sep 16, 2025
CompletionEst.
Nov 1, 2026
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Response rate associated with combination of alirocumab and cemiplimabNow Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 CriteriaTime frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1
Nov 4, 2026
Secondary outcomes
1 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedOverall survivalSurvival (OS)Time frame: Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks
  • AddedNumber of Participants Who Experienced an Adverse EventTime frame: Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason
  • AddedProgression Free Survival (PFS) Per RECIST 1.1. CriteriaTime frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks
  • RemovedSafety and tolerability of the combination regimenTime frame: Day 1 of treatment until 30 days post last dose
  • RemovedProgression Free SurvivalTime frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Response rate associated with combination of alirocumab and cemiplimabNow Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 CriteriaTime frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1
    Secondary outcomes 1 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedOverall survivalSurvival (OS)Time frame: Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks
    • AddedNumber of Participants Who Experienced an Adverse EventTime frame: Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason
    • AddedProgression Free Survival (PFS) Per RECIST 1.1. CriteriaTime frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks
    • RemovedSafety and tolerability of the combination regimenTime frame: Day 1 of treatment until 30 days post last dose
    • RemovedProgression Free SurvivalTime frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05553834
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
May 16, 2023
Primary completion
Sep 16, 2025
Completion
Nov 1, 2026 (estimated)
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alirocumab · Cemiplimab

Start the discussion